Sign Up NowThis Month's Tiny Gems - August 2014

Cinedigm Corp. (CIDM)
Prima BioMed Ltd. (PBMD)
Stellar Biotechnologies, Inc. (SBOTF)




Cinedigm Corp. (CIDM)


Cinedigm (CIDM) is an innovative independent studio that distributes alternative content to theaters across multiple digital media platforms. They offer Exhibitor partners a wide range of selections in digital cinema specifically in the areas of service, installation, equipment vendors, VPF services and equipment financing. The company obtains and distributes award-winning independent movies and alternative content for theatres and digital platforms. Additionally, Cinedigm has played a pioneering role in the evolution of traditional movie theatre film prints to digital delivery.


Cinedigm offers a full line of software solutions that provide more profitable engines of growth for Hollywood studios, content creators, music companies, theatre circuits, and licensors and licensees of intellectual property. They provide professional digital aggregation services for content creators and independent filmmakers such as Indie Direct™ work-for-hire theatrical distribution.


As a major independent content distributor in the U.S., Cinedigm has direct relationships with more than 60,000 digital platforms and retail storefronts, including Target, Wal-Mart, iTunes, Amazon, and Netflix. They also work with cable television providing the Video on Demand platform and they maintain a library of over 52,000 films and TV episodes that include award-winning documentaries from Docurama Films®.


In partnership with WIZARD WORLD, the company has recently announced plans for a Comic Con branded channel scheduled to launch in Q4 2014. They also have plans to launch the Dove Movie Channel, an OTT channel that will stream high quality content that is family friendly and approved by the Dove Foundation.


The Distribution Service acquires and distributes more than 20,000 movies and TV shows from over 650 partners to deliver 40,000 plus hours of television and film across digital media. Cinedigm has designed its infrastructure and technology for future expansion and the company is uniquely positioned to continue its development into emerging digital markets throughout the next decade.




Prima BioMed Ltd. (PBMD)


Prima BioMed (PBMD) is an Australian-based company that develops customized products for immunocellular therapy in the treatment of cancer. They leverage today’s most innovative technologies to enhance and increase treatment options for cancer patients. Prima BioMed offers professional manufacturing capabilities which are comparable between the U.S., Australia, and the EU CMOs.


Prima’s primary product is known as CVac™, an autologous dendritic cell-based substance that is currently undergoing clinical trials for ovarian cancer patients in remission. The company will soon begin a pilot trial for resected pancreatic cancer. Utilizing today’s most groundbreaking logistics and expertise in a GMP facility, the Company is able to provide extensive clinical development services. Their professional and proven CVac distribution logistics and multi-center MNC cell collections work to create consistent batch productions and quality control records.


Their manufacturing and logistics departments provide a wide range of services such as cell collection control, automated labeling, scheduling, and custom shipping material. The product processing is accomplished in three global GMP facilities that are scalable. The carefully scrutinized formulation of the final product is cryo-frozen and has an 18-plus-month stability. The facility has top-notch quality control procedures such as GMP quality antigen, three qualified potency assays, full product characterization, and central electronic QA review.


Prima BioMed has achieved comparability of product manufacturing in three global facilities, Australia, USA, and Germany, producing three consecutive healthy donor batches as required. With demonstrated scale out capabilities of their CVac process, the company’s protocols have been globally accepted and approved. Their demonstrated capability in many areas has paved the way for future scale up into larger facilities.


Prima BioMed is listed on the NASDAQ in the U.S., the Australian stock exchange, and in Germany on the Deutsche Börse in an entry standard. Prima BioMed is committed to maximizing value to its shareholders.




Stellar Biotechnologies, Inc. (SBOTF)


Stellar Biotechnologies, Inc. (SBOTF) is a publicly-held corporation that was founded to address the growing need for Keyhole Limpet Hemocyanin (KLH) protein. Today, they are the world leader in the development and manufacture of high quality KLH products for pharmaceutical use. The company has set unprecedented benchmarks in the proprietary ability to sustainably create GMP grade KLH. They currently operate the only KLH production facility of its kind in the world.


Based in Port Hueneme, California, Stellar Biotechnologies has grown due to its innovative and proactive approach to acquiring sustainable, commercial-grade quantities of KLH for biopharma arenas. KLH has become a significant and versatile molecule that works to stimulate the immune system. It has a long, effective and safe history in the treatment of Alzheimer’s, inflammatory disease, and various types of cancer and new uses are being found each year.


As a world leader in providing KLH-based immunotherapies, Stellar Biotechnologies is also developing its own KLH-conjugate active immunotherapy in order to treat Clostridium difficile infection. The versatility of the KLH molecule has established a consistent requirement for commercial-scale GMP grade KLH, as well as unlimited commercial opportunities for future growth. Among Stellar’s global partners are multinational pharmaceutical companies and distinguished research centers.


Stellar Biotechnologies has utilized decades of specialized aquaculture science to overcome numerous pharmaceutical industry challenges and create an innovative Stellar KLH™ platform that powers the growing field of disease-targeting immune therapies for the modern medical industry. Additionally, Stellar holds key intellectual property directly associated with aquaculture systems, cultivation and protection of the Giant Keyhole Limpet (Megathura crenulata).


Stellar Biotechnologies, Inc. partners with the University of Guelph, Amaran Biotechnology, Bayer Innovations and Neovacs among others. They have over 15 years of KLH production experience, specializing in the controlled production of fully traceable GMP grade KLH. As of May 31, 2014, Stellar showed shareholder’s equity of $11.1 million with about 78 million shares outstanding. Cash and cash equivalents as of May 31, 2014 were $14.8 million, compared to $7.9 million at year-end August 31, 2013.